Axsome Therapeutics Inc
19X
Company Profile
Business description
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Contact
One World Trade Center
22nd Floor
New YorkNY10007
USAT: +1 212 332-3241
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
589
Stocks News & Analysis
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,375.90 | 19.70 | 0.21% |
| CAC 40 | 8,139.20 | 62.20 | 0.77% |
| DAX 40 | 24,152.14 | 29.23 | -0.12% |
| Dow JONES (US) | 46,340.54 | 87.23 | 0.19% |
| FTSE 100 | 9,396.86 | 27.89 | -0.30% |
| HKSE | 25,888.51 | 22.09 | -0.09% |
| NASDAQ | 22,789.64 | 119.56 | 0.53% |
| Nikkei 225 | 48,277.74 | 605.07 | 1.27% |
| NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
| S&P 500 | 6,689.00 | 17.94 | 0.27% |
| S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
| SSE Composite Index | 3,916.23 | 4.02 | 0.10% |